1. NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals
- Author
-
Angelica Cuapio, Caroline Boulouis, Iva Filipovic, David Wullimann, Tobias Kammann, Tiphaine Parrot, Puran Chen, Mira Akber, Yu Gao, Quirin Hammer, Benedikt Strunz, André Pérez Potti, Olga Rivera Ballesteros, Joshua Lange, Jagadeeswara Rao Muvva, Peter Bergman, Ola Blennow, Lotta Hansson, Stephan Mielke, Piotr Nowak, Gunnar Söderdahl, Anders Österborg, C. I. Edvard Smith, Gordana Bogdanovic, Sandra Muschiol, Fredrika Hellgren, Karin Loré, Michal J. Sobkowiak, Giorgio Gabarrini, Katie Healy, Margaret Sällberg Chen, Evren Alici, Niklas K. Björkström, Marcus Buggert, Per Ljungman, Johan K. Sandberg, Soo Aleman, and Hans-Gustaf Ljunggren
- Subjects
Adult ,Male ,COVID-19 Vaccines ,Adolescent ,NK cells ,RM1-950 ,QD415-436 ,Antibodies, Viral ,Biochemistry ,NKG2C ,Immunocompromised Host ,Young Adult ,Outcome Assessment, Health Care ,Genetics ,Humans ,Lymphocyte Count ,Pandemics ,Molecular Biology ,BNT162 Vaccine ,Genetics (clinical) ,Innate immunity ,Cancer och onkologi ,BNT162b2 mRNA vaccine ,SARS-CoV-2 ,Vaccination ,COVID-19 ,Anti-SARS-CoV-2 antibodies ,Middle Aged ,Flow Cytometry ,Killer Cells, Natural ,Clinical trial ,mRNA vaccine ,Cancer and Oncology ,Molecular Medicine ,Female ,Therapeutics. Pharmacology ,NK Cell Lectin-Like Receptor Subfamily C - Abstract
Adaptive immune responses have been studied extensively in the course of mRNA vaccination against COVID-19. Considerably fewer studies have assessed the effects on innate immune cells. Here, we characterized NK cells in healthy individuals and immunocompromised patients in the course of an anti-SARS-CoV-2 BNT162b2 mRNA prospective, open-label clinical vaccine trial. See trial registration description in notes. Results revealed preserved NK cell numbers, frequencies, subsets, phenotypes, and function as assessed through consecutive peripheral blood samplings at 0, 10, 21, and 35 days following vaccination. A positive correlation was observed between the frequency of NKG2C+ NK cells at baseline (Day 0) and anti-SARS-CoV-2 Ab titers following BNT162b2 mRNA vaccination at Day 35. The present results provide basic insights in regards to NK cells in the context of mRNA vaccination, and have relevance for future mRNA-based vaccinations against COVID-19, other viral infections, and cancer.Trial registration: The current study is based on clinical material from the COVAXID open-label, non-randomized prospective clinical trial registered at EudraCT and clinicaltrials.gov (no. 2021–000175-37). Description: https://clinicaltrials.gov/ct2/show/NCT04780659?term=2021-000175-37&draw=2&rank=1.
- Published
- 2022